
Cue Biopharma
(NASDAQ) CUE
Cue Biopharma Financials at a Glance
Market Cap
$117.02M
Revenue (TTM)
$32.73M
Net Income (TTM)
-$19.52M
EPS (TTM)
-$5.53
P/E Ratio
-5.04
Dividend
$0.00
Beta (Volatility)
1.47 (Average)
Dividend
$0.00
Beta (Volatility)
1.47 (Average)
Price
$27.65
Volume
43,602.081
Open
$27.60
Price
$27.65
Volume
43,602.081
Open
$27.60
Previous Close
$27.09
Daily Range
$27.00 - $28.96
52-Week Range
$4.97 - $41.42
Estimated Earnings Date
Aug 18, 2026
Dividend
$0.00
Beta (Volatility)
1.47 (Average)
Price
$27.65
Volume
43,602.081
Open
$27.60
Previous Close
$27.09
Daily Range
$27.00 - $28.96
52-Week Range
$4.97 - $41.42
Estimated Earnings Date
Aug 18, 2026
CUE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cue Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
29
CEO
Usman Azam, MD
Website
www.cuebiopharma.comHeadquarters
Boston, MA 02139, US
CUE Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-60%
Net Income Margin
-60%
Return on Equity
-139%
Return on Capital
-83%
Return on Assets
-63%
Earnings Yield
-19.84%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$117.02M
Shares Outstanding
4.20M
Volume
43.60K
Avg. Volume
745.45K
Financials (TTM)
Gross Profit
$27.47M
Operating Income
-$26.52M
EBITDA
-$22.27M
Operating Cash Flow
-$21.69M
Capital Expenditure
-$177.00K
Free Cash Flow
-$21.86M
Cash & ST Invst.
$27.14M
Total Debt
$4.20M
Cue Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.69M
+1250.6%
Gross Profit
$5.69M
+1250.6%
Gross Margin
100.00%
N/A
Market Cap
$117.02M
N/A
Market Cap/Employee
$2.85M
N/A
Employees
41
N/A
Net Income
-$5.18M
+57.8%
EBITDA
-$4.25M
+62.3%
Quarterly Fundamentals
Total Cash
$16.38M
+24.7%
Total Debt
$3.44M
-51.7%
Accounts Receivable
$5.35M
N/A
Inventory
$0.00
N/A
Long Term Debt
$1.88M
+967.0%
Short Term Debt
$1.56M
-77.5%
Return on Assets
-63.23%
N/A
Return on Invested Capital
-83.39%
N/A
Free Cash Flow
-$11.06M
-32.9%
Operating Cash Flow
-$10.94M
-33.9%

